Diabetes care最新文献

{"title":"About the Editor: Elizabeth Selvin, PhD, MPH-Improvement of Clinical Treatments Through Identification of Biomarkers.","authors":"Benjamin Page","doi":"10.2337/dci25-0086","DOIUrl":"https://doi.org/10.2337/dci25-0086","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 9","pages":"1464"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Griffin et al. Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes. Diabetes Care 2025;48:361-370.","authors":"Sayna Bagheri, Simeon I Taylor","doi":"10.2337/dc25-0961","DOIUrl":"https://doi.org/10.2337/dc25-0961","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 9","pages":"e111-e112"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern. Alam Khan, Mahpara Safdar, Mohammad Muzaffar Ali Khan, Khan Nawaz Khattak, and Richard A. Anderson. Cinnamon Improves Glucose and Lipids of People With Type 2 Diabetes. Diabetes Care 2003;26:3215-3218. DOI: 10.2337/diacare.26.12.3215.","authors":"","doi":"10.2337/dc25-ec09","DOIUrl":"https://doi.org/10.2337/dc25-ec09","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 9","pages":"1646"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stitch in Time: Bariatric Surgery as an Investment for the Future.","authors":"Emma Rose McGlone, Omar Khan","doi":"10.2337/dci25-0063","DOIUrl":"https://doi.org/10.2337/dci25-0063","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 9","pages":"1478-1480"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.","authors":"Henrik Maagensen, Johanne S Jensen, Stine O Høyerup, Anne C B Thuesen, Jesper Krogh, Jens J Holst, Henrik Vestergaard, Peter Rossing, Torben Hansen, Filip K Knop, Sofie Hædersdal, Tina Vilsbøll","doi":"10.2337/dc25-0737","DOIUrl":"10.2337/dc25-0737","url":null,"abstract":"<p><strong>Objective: </strong>Pathogenic variants of HNF1A cause maturity-onset diabetes of the young type 3 (HNF1A-MODY; also known as MODY3). Individuals with HNF1A-MODY are primarily treated with sulfonylureas; however, little is known about the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in HNF1A-MODY. Interestingly, HNF1A-MODY is associated with increased glucosuria, which has been attributed to lower expression of SGLT2 as observed in HNF1A-knockout mice. We investigated the impact of acute SGLT2 inhibition on glucosuria in individuals with HNF1A-MODY or type 2 diabetes.</p><p><strong>Research design and methods: </strong>In a randomized, double-blind, crossover study, individuals with HNF1A-MODY or type 2 diabetes underwent two three-step hyperglycemic clamps targeted at 1-h periods of 10, 14, and 18 mmol/L glucose with and without acute SGLT2 inhibition (25 mg empagliflozin or placebo administrated 2 h before clamp procedures).</p><p><strong>Results: </strong>Eleven individuals with HNF1A-MODY (age [mean ± SD] 49 ± 15 years; glomerular filtration rate [GFR; mean ± SD] 113 ± 18 mL/min) and 10 individuals with type 2 diabetes (age 63 ± 7 years; GFR 103 ± 27 mL/min) were included. During the 3-h hyperglycemic clamp, SGLT2 inhibition increased urinary glucose excretion in both groups (HNF1A-MODY: 24.5 g [95% CI 20.6, 28.3]; type 2 diabetes: 23.5 g [95% CI 20.4, 26.5]). The effect of SGLT2 inhibition was not significantly different between the groups (1.0 g [95% CI -3.5, 5.6]; P = 0.6).</p><p><strong>Conclusions: </strong>The robust effect of SGLT2 inhibition on urinary glucose excretion in participants with HNF1A-MODY points to SGLT2 inhibition as a relevant glucose-lowering treatment strategy in individuals with HNF1A-MODY.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1536-1544"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial.","authors":"Lauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, Jesica Baran, Irl B Hirsch, Bruce W Bode, Sue A Brown, Suzan Bzdick, Mei Mei Church, David W Hansen, Ryan Kingman, Lori M Laffel, Viral N Shah, Sheri Stone, Todd E Vienneau, Lauren M Huyett, Bonnie Dumais, Trang T Ly, Michael C Riddell","doi":"10.2337/dc25-0141","DOIUrl":"10.2337/dc25-0141","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy of enabling Activity feature 60 (AF-60) or 30 min (AF-30) before prolonged exercise versus the automated mode (Auto) in adults and adolescents with type 1 diabetes wearing the Omnipod 5 System.</p><p><strong>Research design and methods: </strong>In this three-way crossover study, 38 participants (age 30 ± 15 years; BMI 24.7 ± 4.1 kg/m2; HbA1c 7.5% ± 0.9% [58 ± 11 mmol/mol]) from the extension phase of the pivotal trial of the Omnipod 5 System completed a 70-min treadmill session at 64-76% maximum heart rate in a postabsorptive state under each of the three conditions. Auto was resumed after exercise, and glycemia and insulin delivery metrics were examined in the 4-h postexercise period.</p><p><strong>Results: </strong>The percentage of participants who developed hypoglycemia during exercise did not differ significantly between Auto (42%) and AF-60 (29%; P = 0.34) or AF-30 (24%; P = 0.14). However, AF-60 and AF-30 reduced insulin delivery compared with Auto in the hour before (P < 0.001) and during exercise (P < 0.001). There was also a favorable attenuation in glucose drop during exercise when comparing Auto (-57 ± -35 mg/dL) with AF-60 (-44 ± -33 mg/dL; P = 0.02) and AF-30 (-36 ± -34 mg/dL; P = 0.01). In the postexercise period, glycemia and insulin delivery were comparable.</p><p><strong>Conclusions: </strong>Enabling the Activity feature either 60 or 30 min before exercise reduced insulin delivery and attenuated glucose drops relative to Auto, but hypoglycemia incidence was not different across the three conditions. These findings support the use of the Omnipod 5 System for exercise but highlight the importance of using additional strategies, such as earlier use of Activity feature and/or carbohydrate intake to further reduce hypoglycemia risk.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1598-1606"},"PeriodicalIF":16.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Li et al. Transition of BMI Status From Childhood to Adulthood and Cardiovascular-Kidney-Metabolic Syndrome in Midlife: A 36-Year Cohort Study. Diabetes Care 2025;48:XXXX-XXXX.","authors":"Ling Li, Huilin Li","doi":"10.2337/dc25-1860","DOIUrl":"https://doi.org/10.2337/dc25-1860","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Pediatric Primary Care Providers Ready for Type 1 Diabetes Screening and Monitoring? A Survey From a Large, U.S. Pediatric Network.","authors":"Christine A March, Pamela Schoemer, Elissa Naame, Ingrid Libman","doi":"10.2337/dc25-1292","DOIUrl":"https://doi.org/10.2337/dc25-1292","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2.","authors":"Naveed Sattar, Gema Frühbeck, Fabrizio Andreelli, Luis-Emilio García-Pérez, Dachuang Cao, Adam Stefanski, Fatih Tangi, Gary Grant, Imane Benabbad","doi":"10.2337/dc25-1442","DOIUrl":"https://doi.org/10.2337/dc25-1442","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Glucose Monitoring Metrics and Pregnancy Outcomes in Women With Gestational Diabetes Mellitus: A Secondary Analysis of the DiGest Trial.","authors":"Laura C Kusinski, Nooria Atta, Danielle L Jones, Suzanne Smith, Louise Cooper, Linda M Oude Griep, Kirsten L Rennie, Emanuella de Lucia Rolfe, Helen R Murphy, Eleanor M Scott, Stephen J Sharp, Roy Taylor, Claire L Meek","doi":"10.2337/dc25-0452","DOIUrl":"10.2337/dc25-0452","url":null,"abstract":"<p><strong>Objective: </strong>Continuous glucose monitoring (CGM) is increasingly used in gestational diabetes mellitus (GDM), but optimal metrics, ranges, and targets in this population are undefined. We assessed associations between CGM metrics and pregnancy outcomes in GDM.</p><p><strong>Research design and methods: </strong>During the DiGest study, 425 women with GDM (diagnosed at median [IQR] 25.1 [18.3-27.7] weeks) and BMI ≥25 kg/m2 received a dietary intervention, with masked Dexcom G6 CGM at 29 (n = 361), 32 (n = 215), and 36 (n = 227) weeks' gestation. For this secondary analysis, we used logistic regression, receiver operating characteristic curves, and the Youden index to assess associations and predictive ability of CGM metrics, including pregnancy-specific time in range (TIRp) (63-140 mg/dL [3.5-7.8 mmol/L]) and pregnancy outcomes.</p><p><strong>Results: </strong>CGM metrics at 29 weeks were significantly associated with large for gestational age (LGA) and small for gestational age (SGA). Participants achieving mean glucose <110 mg/dL (6.1 mmol/L), TIRp ≥90%, or pregnancy-specific time above range (TARp) <10% at 29 weeks had a significantly lower risk of LGA (odds ratio [OR] 0.41 [95% CI 0.22, 0.77], 0.38 [0.20, 0.70], and 0.39 [0.20, 0.73], respectively) and SGA (0.26 [0.08, 0.79], 0.30 [0.10, 0.91], and 0.19 [0.06, 0.62], respectively). TARp <10% and mean nocturnal glucose <110 mg/dL (6.1 mmol/L) were associated with a reduced odds of preterm birth (OR 0.40 [0.17, 0.94] and 0.42 [0.19, 0.97], respectively). A stricter range (63-120 mg/dL [3.5-6.7 mmol/L]) had similar performance overall, but had no single statistically robust TIR/TAR target across all outcomes.</p><p><strong>Conclusions: </strong>In women with GDM, CGM mean glucose <110 mg/dL (6.1 mmol/L), ≥90% TIRp, or <10% TARp using a range of 63-140 mg/dL (3.5-7.8 mmol/L) at 29 weeks' gestation was associated with a low risk of suboptimal offspring outcomes.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144884603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}